Eli Lilly's rare stumble

Plus: Bird flu found in a pig in U.S. for the first time, raising concerns about potential risks to humans

October 30, 2024 Check out STAT+

Sponsored By

Accurate watchdog journalism is essential for a more equitable and informed world, and STAT is committed to upholding this standard in all our reporting. We're currently offering 40% off our annual news subscription. If you value uncompromising journalism that demands accountability in health care, biotech, and medicine, please consider supporting our newsroom today.

Adobe STAT+ | Eli Lilly hits rare stumble, as sales and earnings disappoint The company's quarterly earnings report comes as it faces off with compounding pharmacies amid questions about shortages of its drug. By Elaine Chen AstraZeneca's China president is under investigation by authorities One Chinese government probe is reportedly related to collection of patient data, and whether that infringed data-privacy laws. By Ed Silverman STAT+ | Novo Nordisk's Ozempic and Wegovy, long in shortage, are now listed as available by FDA It remains unclear how the agency's update on semaglutide could affect patients as well as compounding pharmacies. By Elaine Chen NIAID Bird flu found in a pig in U.S. for the first time, raising concerns about potential risks to humans Danger of H5N1 bird flu in pigs is that it could produce a version that heightens risk for humans. Pigs have a history of hosting flu viruses that jump to people. By Helen Branswell National Academies calls to change how biomedical research uses race and ethnicity Race and ethnicity are applied in inappropriate and even harmful ways in biomedical research, the National Academies said in a report. By Katie Palmer and Usha Lee McFarling STAT+ | Early data from Roche's Alzheimer's therapy show it's hitting targets The company is testing an amyloid-clearing antibody with its Brainshuttle tool, which helps drugs reach into the brain. By Andrew Joseph Photo illustration: Christine Kao/STAT; Photos: Adobe, Venrock, Georgian, Oak HC/FT STAT+ | Health tech investments are picking up steam. Here are 5 VC leaders behind the biggest recent deals As investments in health tech ventures start to gain momentum, STAT takes a look at the VCs behind some of the biggest recent deals. By Mohana Ravindranath

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser